A Phase I Pharmacokinetic And Pharmacodynamic Study Of PF-03446962 In Asian Patient With Advanced Solid Tumors
Phase 1
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Neoplasms
Both
Neoplasms
Trial Information
A Phase I Pharmacokinetic And Pharmacodynamic Study Of PF-03446962 In Asian Patient With Advanced Solid Tumors
Inclusion Criteria:
- Confirmed diagnosis of stomach cancer
- advanced/metastasis solid tumor refractory or intolerant to established therapy
- adequate blood chemistry, blood counts and kidney/liver function
- willing to participate to study requirements and sign an informed consent document
Exclusion Criteria:
- Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of
first dose of study medication
- excessive toxicities related to prior therapies
- pregnant or breastfeeding patients
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Outcome Measure:
Maximum Tolerated Dose
Outcome Time Frame:
12 months
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A8471004
NCT ID:
NCT01337050
Start Date:
July 2011
Completion Date:
June 2013
Related Keywords:
- Neoplasms
- Hepatocellular Carcinoma
- Advanced/Metastatic solid tumors
- Neoplasms
Name | Location |
|---|
